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Related to the underlying DNA repair defect that is the hallmark of Fanconi anemia (FA), preparatory reg-
imen-related toxicities have been obstacles to hematopoietic cell transplantation (HCT). In an attempt to
decrease the risk and severity of regimen-related toxicities, nonirradiation regimens have been explored.
The aim of this study is to compare outcomes after irradiation and nonirradiation regimens in 148 FA patients
and identify risk factors impacting upon HCToutcomes. Hematopoietic recovery, acute and chronic graft-
versus-host disease (aGVHD, GVHD), and mortality were similar after irradiation and nonirradiation regi-
mens. In both groups of recipients aged.10 years, prior use of androgens and cytomegalovirus seropositiv-
ity in either the donor or recipient were associated with higher mortality. With median follow-ups.5 years,
the 5-year probability of overall survival, adjusted for factors impacting overall mortality was 78% and 81%
after irradiation and nonirradiation regimens, P5 .61. In view of the high risk of cancer and other radiation-
related effects on growth and development, these results support the use of nonirradiation preparatory reg-
imens. As the peak time for developing solid tumors after HCT is 8 to 9 years, longer follow-up is required
before definitive statements can be made regarding the impact of nonirradiation regimens on cancer risk.
Biol Blood Marrow Transplant 14: 1141-1147 (2008)  2008 American Society for Blood and Marrow Transplantation
KEY WORDS: Fanconi anemia, Matched sibling donor, Conditioning regimen, Survival, Graft-versus-host
diseaseINTRODUCTION
Fanconi anemia (FA) is characterized by congeni-
tal malformations, progressive marrow failure, and
marked predisposition to leukemia, myelodysplasia,
and epithelial malignancies [1-7]. Hematologic abnor-
malities occur in almost all patients with FA at amedian
age of 7 years [4,5]. Allogeneic hematopoietic cell
transplantation (HCT) from anHLA-compatible fam-
ily member or unrelated donor is currently the onlyway to restore normal hematopoiesis [8-10]. Overall
survival (OS) rates of approximately 80% are reported
after HLA-matched sibling donor transplantation us-
ing cyclophosphamide (Cy) and limited field irradia-
tion [11]. Yet, regimen-related toxicities such as
growth retardation, acute and chronic graft-versus-
host disease (aGVHD, cGVHD), and epithelioid ma-
lignancies remain major challenges for these patients
[8,11-13]. Although it is not anticipated that the risks
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in FA patients not treated by HCT, elimination of ra-
diation from the preparatory regimen may not only
minimize the impact of HCT on risk of cancer but
also reduce known radiation effects on growth and de-
velopment. For this reason, a number of groups have
explored conditioning regimens that do not contain ir-
radiation [11,14-17]. These reports are limited in
numbers of patients studied. In this report we compare
the early outcomes using nonirradiation containing
conditioning regimens (n 5 71) to outcomes of regi-
mens with irradiation (n 5 77) for FA patients trans-
planted from HLA-matched siblings.
MATERIAL AND METHODS
Data Source
The Center for International Blood and Marrow
Transplant Research (CIBMTR) is a research affilia-
tion of the International Bone Marrow Transplant
Registry (IBMTR) and the National Marrow Donor
Program that are comprised of a voluntary working
group of over 400 transplant centers worldwide that
contribute data on consecutive allogeneic HCTs.
Participating centers register all transplantations con-
secutively. Patients are followed longitudinally, with
yearly follow-up. The CIBMTR collects data at 2
levels: registration and research. Registration data in-
clude disease type, age, sex, pretransplant disease stage
and chemotherapy responsiveness, date of diagnosis,
graft type, conditioning regimen, GVHD prophylaxis,
posttransplant disease status and survival, development
of a newmalignancy, and cause of death. Research data
are collected on selected subsets of registered patients
and includes comprehensive pre- and posttransplant
clinical information. Computerized checks for errors,
physician reviews of submitted data, and on-site audits
of participating centers ensure the quality of data.
Eligibility Criteria
One hundred forty-eight patients receiving their
first HLA-matched sibling bone marrow transplant
for FA between 1991 and 2001, and reported to the
CIBMTR, were eligible. Seventeen patients who re-
ceived grafts other than bone marrow from a matched
family donor were excluded (11 peripheral blood
progenitor cells and 6 umbilical cord blood).
Seventy-seven of 148 patients received irradiation-
containing regimens and 71 nonirradiation-condition-
ing regimens. Transplantations were performed at 35
centers in 16 countries worldwide.
Endpoints
The primary endpoints were neutrophil and
platelet recovery, aGVHD and cGVHD, and OS.
Neutrophil recovery was defined as achieving an abso-lute neutrophil count (ANC) $0.5  109/L for 3
consecutive days. Platelet recovery was defined as
achieving a platelet count $20  109/L, unsupported
by transfusions for at least 7 days. Diagnosis of
aGVHD and cGVHD [18,19] was based on local insti-
tutional criteria, with the overall grade of aGVHD as-
signed retrospectively by the CIBMTR based on stage
of involvement reported for each individual organ.
Surviving patients were censored at last follow-up.
Statistical Analysis
Patient-, disease-, and transplant-related variables
for the 2 treatment groups were compared using the
chi-square statistic for categoric and the Kruskal-
Wallis for continuous variables (Table 1). All patients
were censored at 5 years for evaluation of posttrans-
plant outcomes. The probability of OS was calculated
using the Kaplan-Meier estimator [20]. Probabilities
of neutrophil and platelet recovery and aGVHD and
cGVHD were calculated using a cumulative incidence
estimator [21]. Ninety-five percent confidence inter-
vals (CI) were calculated using log transformation.
Risk factors associated with overall mortality were
examined using Cox proportional hazards regression
[22]. All models were built using a forward stepwise
method with a P-value of #.05 to indicate statistical
significance. Variables that met the criteria for statisti-
cal significance were held in the final model. The vari-
able for conditioning regimen (irradiation versus
nonirradiation conditioning regimens), the main vari-
able of interest was held in all steps of model building
regardless of level of significance. Other variables
tested include: age at transplantation (#10 versus
.10 years), performance score (90-100 versus\90),
androgen therapy pretransplant, physical abnormali-
ties (#3 versus.3 sites), time from diagnosis to trans-
plantation (#18 versus .18 months), donor-recipient
cytomegalovirus (CMV) sero status (donor/recipient
negative versus either or both donor/recipient
positive), and year of transplant (1991-1995 versus
1996-2001). We examined for an effect of transplant
center on OS and found none [23]. All analyses were
performed using SAS version 9.1 (SAS Institute,
Cary, NC).
RESULTS
Patient, Disease, and Transplant Characteristics
Patient, disease, and transplant characteristics were
similar between the 2 treatment groups except that re-
cipients of nonirradiation regimens weremore likely to
have physical abnormalities in.3 sites and transplants
with nonirradiation regimens were likely to be more
recent (Table 1). The most frequent indication for
transplantation was aplastic anemia (PA, n 5 134);
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Sibling Transplants
Conditioning Regimen
Irradiation Nonirradiation
Variables N N (%) N N (%) P-Value
Number of patients 77 71
Number of centers 23 12
Age at transplant 77 71 .67
#10 years 45 (58) 39 (55)
11-20 years 32 (42) 32 (45)
Male 77 45 (58) 71 34 (48) .20
Performance score pretransplant 77 71 .07
<90 13 (17) 21 (30)
$90 63 (82) 49 (69)
Unknown 1 (1) 1 (1)
Pretransplant therapy
Androgens 77 71 .21
Yes 26 (34) 17 (24)
No 49 (64) 51 (72)
Unknown 2 (3) 3 (4)
Physical abnormalities 77 71 .01
#3 sites 41 (53) 27 (38)
>3 sites 26 (34) 42 (59)
Unknown 10 (13) 2 (3)
Conditioning regimen* 77 71 NA
Radiation containing
TLI/TAI + Cy + ATG 29 (38) __
TBI + Cy ± ATG 20 (26) __
TLI/TAI + Cy 28 (36) __
Nonradiation containing
Cy alone __ 45 (63)
Cy + ATG __ 17 (24)
Bu + Cy __ 3 (4)
Fludarabine + Cy† __ 6 (9)
Donor-recipient CMV status 77 71 .01
Donor +/recipient + 31 (41) 45 (63)
Donor +/recipient 2 11 (14) 7 (10)
Donor -/recipient + 11 (14) 10 (14)
Donor -/recipient 2 23 (30) 8 (11)
Unknown 1 (1) 1 (2)
Year, transplant 77 71 <.001
1991-1994 45 (58) 23 (32)
1995-2001 32 (42) 48 (68)
Median follow-up of survivors, months 77 96 (9-153) 71 58 (16-143)
*Regimen doses are:
 Limited field irradiation + cylocphosphamide 6 antithymocyte globulin
B Limited field irradiation dose: 400-600 cGy
B Cyclophosphamide dose: 20 mg/kg
 Total body irradiation + cyclophosphamide 6 antithymocyte globulin
B Total body irradiation dose: 500 cGY
B Cylophosphamide dose: 20-60 mg/kg
 Cyclophosphamide 6 antithymocyte globulin
B Cyclophosphamide dose: 60-200 mg/kg
 Busulfan + cyclophosphamide
B Busulfan dose: 8 mg/kg
B Cyclophosphamide dose: 20-80 mg/kg
 Fludarabine + cyclophosphamide
B Fludarabine dose: 120-180 mg/m2
B Cyclophosphamide dose: 20-80 mg/kg
† Regimen includes:
 Fludarabine + cyclophosphamide + antithymocyte globulin (n 5 4); Fludarabine + cyclophosphamide + Campath (n 5 2)8 patients were transplanted for leukemia and 6 for iso-
lated thrombocytopenia. A third of patients in the
irradiation group and 24% in the nonirradiation group
received androgens prior to transplantation. All
patients received bone marrow grafts; none were T
cell depleted. GVHD prophylaxis consisted ofcyclosporine (CSA) for all patients, with short-course
methotrexate (MTX) in 75 patients. All except 1 pa-
tient received#20 red blood cell transfusions pretrans-
plant. Total nucleated cell dose was reported in 132 of
148 (89%) patients; approximately a third of patients
were infused with grafts #3.0  108/kg. The median
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diation regimen and 5 years after nonirradiation regi-
mens. To account for the differential follow-up
between treatment groups, all patients were censored
at 5 years for evaluation of posttransplant outcomes.
Hematopoietic Recovery
The median time to neutrophil recovery was 13
days and 17 days after irradiation-containing and non-
irradiation regimens, respectively. The day-28 proba-
bility of neutrophil recovery was similar after
irradiation-containing and nonirradiation regimens;
94% (95% CI 86-98) and 89% (95% CI 80-96),
P 5 .35. Two patients failed to achieve neutrophil
recovery after irradiation-containing regimens, and 3
after nonirradiation regimens. Recovery times were
slower in patients who received CsA and short-course
MTX (relative risk [RR] 0.63, 95% CI 0.44-0.91, P 5
.01). The day 100 probability of platelet recovery was
similar after irradiation-containing and nonirradiation
regimens; 92% (95% CI 85-97) and 92% (95% CI 84-
97). Secondary graft failure rates were low (n 5 5); 4
cases after irradiation containing regimens (graft fail-
ure occurred at 4 months, 15 months [n 5 2], and 39
months after transplantation) and 1 after a nonirradia-
tion-containing regimen that occurred at 9 months.
GVHD
The day 100 probabilities of acute grade II-IV
GVHD were similar after irradiation-containing and
nonirradiation regimens, 23% (95% CI 15-33) and
21% (95% CI 13-31), P 5 .74, respectively. The cor-
responding probabilities of grades III-IV aGVHD
were 6% (95% CI 2-13) and 10% (95% CI 4-18), P
5 .46. The 5-year probabilities of cGVHD were
18% (95% CI 10-28) and 24% (95% CI 14-35), after
irradiation-containing and nonirradiation regimens,
respectively (P 5 .40).
Table 2. Multivariate Analysis Showing Risks of Overall
Mortality after HLA-Matched Sibling Transplants in Patients
with FA
Variables N
Relative Risk
(95% Confidence Interval)
P-
Value
Main effect:
Radiation 74 1.00
Nonradiation 68 0.96 (0.46-1.99) .904
Other significant covariates:
Age at transplant:
#10 years 79 1.00
>10 years 63 4.24 (1.81-9.93) <.001
Androgen therapy:
No 100 1.00
Yes 42 2.62 (1.26-5.44) .008
Donor-recipient CMV status:
Both negative 31 1.00
Either or both positive 111 4.67 (1.08-20.11) .039Overall Mortality
Risks of mortality were similar after irradiation-
containing and nonirradiation regimens, adjusted for
other factors associated with mortality (Table 2).
Older patient age (.10 years), use of androgens pre-
transplant and CMV seropositivity in the donor and/
or recipient were associated with higher mortality
risks. The 5-year probabilities of OS adjusted for the
above-mentioned significant factors were 78% (95%
CI 67-85) and 81% (95% CI 71-88) after irradiation-
containing and nonirradiation regimens, respectively
(P 5 .61). Mortality rates were higher in patients
with aGVHD and cGVHD (RR 3.47, 95% CI 1.64-
7.33, P 5 .001 and RR 4.06, 95% CI 1.63-10.12,
P 5 .003), respectively.
Four patients developed malignant neoplasm
(squamous cell carcinoma). These patients were trans-
planted at 7, 10, 14, and 20 years of age. Two patients
received irradiation-containing regimens and devel-
oped squamous cell carcinoma (SCC) at 55 and 101
months after HCT. The remaining 2 patients received
nonradiation regimens and developed SCC at 58 and
60 months, post-HCT. One patient had a history of
aGVHD, and 2 patients cGVHD. Only 1 patient re-
ceived azathioprine for treatment of cGVHD.
Thirty-one patients died, 16 after irradiation-con-
taining regimens and 15 after nonirradiation condi-
tioning regimens. Most deaths occurred within 2
years after transplantation; 14 after irradiation con-
taining regimens, and 12 after nonirradiation regi-
mens. Causes of death did not differ by conditioning
regimen. The most common causes of death within
the first 2 years after transplantation were infections
(n 5 6), organ failure (n 5 6), and GVHD (n 5 5).
Death after the first 2 years after transplantation
were infections (n 5 2), hemorrhage (n 5 1), and
SCC of the tongue (n 5 1) (Table 3).
DISCUSSION
Transplantation of hematopoietic stem cells from
an HLA-matched sibling, when such a donor is avail-
able, is the treatment of choice for the bone marrow
failure syndrome that characterizes FA. The
Table 3. Causes of Death
Within 2 Years
of BMT
Beyond 2 Years
from BMT
Causes of death N eval N N eval N
Number of patients 26 5
Graft failure 3 0
Infection 6 2
GVHD 5 0
Organ failure 6 0
Hemorrhage 2 1
Squamous cell carcinoma 0 1
Other 4 1
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ited field irradiation led to significant improvements
in survival [8,11]. FA patients are predisposed to devel-
oping epitheliod carcinomas after the age of 20 years
regardless of whether they undergo transplantation
[24]. Deeg and colleagues [12] identified irradiation-
containing conditioning regimens as a risk factor for
posttransplant malignancy in patients with FA. Conse-
quently, there has been increasing interest in the use of
nonirradiation-containing regimens for FA, particu-
larly if an HLA-matched sibling donor is available.
In this study we have explored outcomes in a relatively
large group of recipients of HLA-matched sibling
transplants using irradiation and nonirradiation condi-
tioning regimens.
The current report identified 3 factors associated
with higher mortality: use of androgens pretransplant,
age at transplant (.10 years), and CMV seropositivity
in the donor and/or recipient. Use of androgens
pretransplant for marrow aplasia is controversial.
Although oxymetholone and other androgens have
been reported to improve blood counts in approxi-
mately 50% of patients, side effects are substantial,
including masculinzation, peliosis hepatitis, and he-
patic adenoma. Furthermore, the effectiveness of an-
drogen treatment is of limited duration [1]. For these
reasons and the fact that there is a high probability of
survival after an HLA-matched sibling transplant, an-
drogens are generally avoided when an HLA-matched
sibling is available.
Age at transplantation is also an adverse risk factor
[9,11,25]. Although it is not recommended that trans-
plant be performed before marrow failure, less toxic
preparatory therapies and alternate approaches for
preventing GVHD are needed to reduce regimen-re-
lated toxicities. Similarly, CMV seropositivity in the
donor and/or recipient and its adverse effect on mor-
tality has also been reported by others for FA [9,26].
Although deaths are not often directly because of
CMV, this may be a surrogate marker for delayed
immune recovery. New strategies for reducing the
period of immunodeficiency are required.
Other reported risk factors include transfusion ex-
posure and the presence of .3 congenital malforma-
tions. Higher mortality in recipients of over 20
pretransplant transfusions has been previously re-
ported [8,25]. In the current report, all patients but 1
received #20 red blood transfusions, and approxi-
mately 80% received #10 or fewer red blood cell
transfusions, indicating that patients with HLA-
matched siblings are referred for transplantation in
a timelier manner since the publication of the above-
mentioned reports. Although we were unable to find
an association between numbers of red blood cells
transfused pretransplant (#10 versus.10), the current
analysis may not be sufficiently powered to defect
a meaningful difference between the groups. We alsoexamined the impact of congenital malformations
and found none. This contrasts with an earlier
EBMT report where mortality rates were higher in
patients with 3 or more congenital abnormalities after
unrelated donor HCT [24] and from the Hopital Saint
Louis, where aGVHD rates were higher in patients
with urogenital malformations after HLA-matched
sibling HCT [13].
We observed similar rates of aGVHD and
cGVHD after radiation and nonirradiation regimens.
aGVHD rates after irradiation regimens in this report
was 23% and lower to aGVHD rates of 62% observed
at Hopital Saint Louis where the conditioning regi-
men contained limited field irradiation [13]. The lower
rate in this report may be explained by the use of an-
tithymocyte globulin (ATG) in over 60% of patients
who received limited field irradiation. We were unable
to identify risk factors associated with aGVHD or
cGVHD in this analysis. This is not unexpected, given
the relatively small numbers of patients and few events.
However, the proportion of patients with aGVHD or
cGVHD was lower in patients who received ATG
(data not shown). The occurrence of aGVHD or
cGVHD had an adverse impact on mortality, confirm-
ing the observations of others that GVHD is a major
limitation to a successful outcome after transplanta-
tion in FA.
With 5-year OS rates of approximately 80%, phy-
sicians must be encouraged to refer FA patients with an
HLA-matched sibling for transplantation as soon as
aplasia develops. Avoidance of androgens and minimal
transfusion prior to transplantation can only further
improve the OS rate. GVHD remains a limitation;
mortality rates are higher, as are risks of SCC. The
use of ATG may have lowered GVHD rates but the
duration of immune suppression is longer and the pa-
tient subject to opportunistic infections and conse-
quent morbidity and mortality. As the peak onset for
malignant neoplasms tend to occur later than 5 years
(the median follow-up of this cohort) after HCT, lon-
ger follow-up is required to determine whether its
prevalence after nonirradiation regimens will remain
similar to that after radiation regimens as observed.
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